Clinical trial
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
NCT02552849 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 25, 2013
- Completion date
- August 15, 2017
- Enrollment
- 305 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.